Inivata Raises £4m in Funding

Inivata, a Cambridge, UK-based clinical cancer genomics company, raised £4m in funding.

The round was led by Imperial Innovations with participation from Cambridge Innovation Capital and Johnson & Johnson Development Corporation.

Led by Michael Stocum, CEO, Inivata focuses on harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment through collaborations with clinical oncologists at academic institutions, community treatment centres and innovative biopharmaceutical companies.

Novel applications of ctDNA are enabled by the company’s technology platform which includes its proprietary, enhanced TAm-Seq™ technology. TAm-Seq, which is licensed to Inivata from Cancer Research Technology and the University of Cambridge, allows the detection and analysis of genomic material from a cancer patient’s cell-free ctDNA collected through routinely accessible blood samples.



Join the discussion